CV Risk Master Class
Asian chapter - Kuala Lumpur, Malaysia - May 10-11, 2013

An educational alliance to optimize management of cardiovascular disease
This Master Class program is a global initiative of the Physicians’ Academy for Cardiovascular Education(PACE) foundation with a particular focus on issues and opportunities in cardiovascular risk and lipid management in high risk patients.This CV Risk Master Class are dynamic meetings with state of the art lectures, clinical debates, and practical workshops. Participants are part of an educational initiative that will provide support to clinicians in their daily clinical management of cardiovascular risk and diabetes. The program provides an optimal balance between updates in forefront science and clinical dialogue, with involvement of international and regional thought leaders.
The PACE International programme directors are:
- Prof. John E. Deanfield, London
- Prof. D. John Betteridge, London
- Prof. John J.P. Kastelein, Amsterdam
View all lectures via archived webcast
|

Novel therapies for the prevention of atherosclerotic vascular disease
Teaching slides prepared and presented by Prof John Kastelein, AMC, Amsterdam, at the CV Risk Master Classes in May 2013
Novel therapies for the prevention of atherosclerotic vascular disease
Teaching slides prepared and presented by Prof John Kastelein, AMC, Amsterdam, The Netherlands at the Cardiovascular Risk Master Classes in May 2013
Hypertension and cardiovascular disease
49 Teaching slides addressing hypertension and cardiovascular disease, blood pressure managent.
Macrovascular disease in diabetes
Teaching slides addressing macrovascular disease in diabetes and lipid management
Landmark statin trials across the spectrum of risk: Secondary stroke prevention
Teaching slides addressing secondary stroke prevention and statin therapy
Cardiovascular Risk: A global issue
Teaching slides addressing the global issues and epidemiology of cardiovascular disease and different risk factors
Landmark trials with statins
An overview of slides Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention
Share this page with your colleagues and friends: